Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Liabilities (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Total Liabilities for 10 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 16.35% to $7.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.5 million, a 16.35% decrease, with the full-year FY2024 number at $7.8 million, up 1.13% from a year prior.
  • Total Liabilities was $7.5 million for Q3 2025 at Rein Therapeutics, down from $9.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $9.5 million in Q2 2025 to a low of $1.2 million in Q2 2023.
  • A 5-year average of $5.5 million and a median of $4.7 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 76.76% in 2023, then skyrocketed 600.0% in 2024.
  • Rein Therapeutics' Total Liabilities stood at $4.6 million in 2021, then fell by 26.07% to $3.4 million in 2022, then skyrocketed by 127.87% to $7.7 million in 2023, then grew by 1.13% to $7.8 million in 2024, then dropped by 3.62% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Total Liabilities are $7.5 million (Q3 2025), $9.5 million (Q2 2025), and $7.7 million (Q1 2025).